A Phase 2 Placebo-Controlled, Randomized, Double Blind, Adaptive Dose Trial of the Safety and Efficacy of Inhaled AZD1419 in Adults With Eosinophilic, Moderate to Severe Asthma

Trial Profile

A Phase 2 Placebo-Controlled, Randomized, Double Blind, Adaptive Dose Trial of the Safety and Efficacy of Inhaled AZD1419 in Adults With Eosinophilic, Moderate to Severe Asthma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs AZD 1419 (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms INCONTRO
  • Sponsors Dynavax Technologies
  • Most Recent Events

    • 21 Sep 2017 Planned End Date changed from 11 Oct 2018 to 3 Sep 2018.
    • 21 Sep 2017 Planned primary completion date changed from 11 Oct 2018 to 3 Sep 2018.
    • 21 Sep 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top